Lesson
Build the Sweat-Control Circuit
Sweating is a protective output, not simply a nuisance. The hypothalamus, sympathetic cholinergic nerves, muscarinic receptors, eccrine coils, ducts, and evaporation form a control system that treatment must partially suppress without defeating thermoregulation.
- Eccrine gland
- Acetylcholine
- Muscarinic receptor
- Evaporation
- Thermoregulation
Central circuits set the response
Acetylcholine reaches the gland
Eccrine coils move fluid to skin
Sweat protects core temperature
Separate gland types
Eccrine glands are widely distributed and central to cooling. Apocrine secretion contributes more to axillary odor biology and is not the main thermoregulatory target.
Trace the unusual sympathetic pathway
Postganglionic sympathetic fibers release acetylcholine onto muscarinic receptors at eccrine glands. This cholinergic terminal is an important exception to the common adrenergic pattern.
Connect sweat to cooling
Sweat lowers temperature only when it evaporates. Humidity, occlusive clothing, dehydration, and impaired airflow reduce cooling even when sweat production is high.
Distinguish trigger circuits
Heat and exercise recruit broad thermoregulatory sweating. Emotion can disproportionately affect palms, soles, axillae, and face. Trigger pattern helps map disease but does not prove its cause.
Quick check
Checking for saved practice…
Lesson
Diagnose the Pattern Before Suppressing It
Primary focal disease is commonly bilateral, longstanding, frequent, and functionally disruptive. New generalized, nocturnal, asymmetric, medication-linked, or systemic sweating requires a cause search.
- Primary focal
- Secondary
- Medication review
- HDSS
- Red flags
Axillae, palms, soles, face, or whole body
Primary disease is often longstanding and bilateral
Endocrine, infection, malignancy, neurologic, and drug causes
Severity is defined by function, not sweat alone
Recognize primary focal disease
Typical clues include focal bilateral sweating, onset earlier in life, recurrent episodes, family history, and reduced sweating during sleep. Axillae, palms, soles, and craniofacial areas are common sites.
Recognize secondary disease
Endocrine disorders, infection, malignancy, neurologic disease, menopause, hypoglycemia, cardiopulmonary illness, substances, withdrawal, and medications can produce excessive sweating.
Reconcile the medication list
Antidepressants, opioids, hypoglycemic therapies, cholinergic drugs, and withdrawal states are examples. Timing around starts, dose changes, nonadherence, and discontinuation is more useful than a static list.
Measure what matters
The Hyperhidrosis Disease Severity Scale and patient-defined outcomes capture interference with work, school, grip, clothing, sleep, skin integrity, and social function. A single office observation can underestimate burden.
Quick check
Checking for saved practice…
Lesson
Make Antiperspirant Technique Work
Aluminum antiperspirants reduce sweat by forming temporary duct plugs. Technique, skin dryness, application timing, induction frequency, and irritation control determine whether an inexpensive first strategy succeeds.
- Aluminum salts
- Duct plug
- Dry skin
- Bedtime
- Maintenance
Moisture increases irritation
Treat the sweating field
Sweat output falls with repeated use
Step down after control
Distinguish antiperspirant from deodorant
Antiperspirants reduce sweat output. Deodorants reduce or mask odor. Combination products may do both, but a deodorant-only product cannot substitute for antiperspirant pharmacology.
Choose the aluminum preparation
OTC clinical-strength products are often tried first; prescription aluminum chloride hexahydrate 20% is a common next option for axillary disease. Follow the specific formulation instructions rather than treating deodorants and different aluminum salts as interchangeable.
Apply to completely dry skin
Bedtime application allows longer contact during lower sweat output. Water can increase formation of irritating acidic species, so skin should be dry and intact.
Protect the barrier
Avoid application immediately after shaving or on broken skin. A thin, even film is preferable to repeated heavy application. Adjust frequency or formulation if dermatitis develops.
Move from induction to maintenance
For prescription aluminum chloride, a typical initial course is nightly for about one week as tolerated, washing it off 6 to 8 hours after application. Once controlled, extend the interval, often to weekly or less. Irritation calls for reassessment of skin dryness, formulation and frequency rather than heavier application.
Quick check
Checking for saved practice…
Lesson
Compare Axillary Anticholinergic Delivery
Qbrexza glycopyrronium cloth and Sofdra sofpironium gel reduce axillary sweating by competitively inhibiting acetylcholine signaling at peripheral sweat glands. Their dosage forms, instructions, metabolism, and interaction profiles are not interchangeable.
- Glycopyrronium
- Sofpironium
- Muscarinic receptor
- Quaternary ammonium
- Axillary delivery
Eccrine stimulation decreases
Axillary labeling is product specific
Broken skin and occlusion increase risk
Prevent eye transfer and mydriasis
Connect structure to action
Both active drugs contain a permanently charged pyrrolidinium center and competitively inhibit peripheral acetylcholine receptors. The charge favors peripheral behavior but does not eliminate systemic absorption or toxicity.
Use Qbrexza as labeled
One premoistened 2.4% glycopyrronium cloth is wiped once across one clean dry axilla and then once across the other, no more often than every 24 hours. Discard in household trash inaccessible to children and others, then wash hands immediately with soap and water. Accidental contact with discarded cloths has caused pupil dilation and blurred vision. Qbrexza is flammable: keep storage and application away from heat and flame.
Use Sofdra as labeled
Sofdra 12.45% gel uses one pump per clean, dry axilla at bedtime, spread with its applicator rather than fingers. For 8 hours beforehand, avoid shaving and deodorant; for 30 minutes beforehand, avoid exercise and washing. Let it dry completely for 5 minutes before dressing, keep it away from flames and smoking, and leave the underarms unwashed for at least 8 hours. Do not touch treated underarms; wash hands immediately with soap and water.
Prime and maintain the Sofdra dispenser
Prime each new bottle over a sink with 1 to 2 full presses or until gel appears, and rinse discarded gel away without touching or using it. After each application, rinse and dry the applicator. Discard the bottle and applicator after 30 daily doses; do not increase pumps for larger underarms.
Understand exposure differences
Sofpironium undergoes nonenzymatic hydrolysis and oxidative metabolism, including CYP2D6. Its label directs avoiding strong CYP2D6 inhibitors, not merely monitoring the combination. Both topical products also direct avoiding concomitant anticholinergic drugs because effects can add. Review the complete medication list before prescribing; do not independently stop necessary medicines. Neither product belongs on broken skin, under occlusion, or on unapproved body sites.
Quick check
Checking for saved practice…
Lesson
Protect the Bladder, Eyes, and Heat Response
Topical anticholinergic therapy can still produce local and systemic effects. Labeled contraindications, other anticholinergic medicines, urinary obstruction, visual symptoms, and hot environments define the safety margin.
- Contraindications
- Urinary retention
- Blurred vision
- Heat illness
- Additive burden
Some conditions can worsen
Other medicines add toxicity
Cooling can fail
Escalate promptly
Apply labeled contraindications
Conditions that can worsen with anticholinergic effects include glaucoma, paralytic ileus, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren syndrome, and unstable cardiovascular status in acute hemorrhage. Apply the actual product contraindications rather than narrowing the glaucoma warning to an assumed subtype.
Recognize retention early
Urinary hesitation, weak stream, incomplete emptying, suprapubic distention, or pain should prompt immediate discontinuation and clinical review, especially with prostatic or bladder-neck obstruction.
Protect vision and safety
Periocular transfer can cause mydriasis and transient blurred vision. Stop the product and avoid driving, machinery, or hazardous work until vision is clear. Eye pain or persistent symptoms need evaluation.
Prevent heat illness
Generalized lack of sweating in high heat can progress to hyperpyrexia or heat stroke. Stop treatment if generalized lack of sweating develops in hot conditions and contact the prescriber; confusion, collapse or severe overheating requires emergency care. Review climate, work, sports, hydration, other anticholinergics, and the emergency signs of confusion, collapse, or severe overheating.
Quick check
Checking for saved practice…
Lesson
Escalate With Site-Directed Procedures
When topical treatment is inadequate, focal procedures can reduce sweating without treating the entire body. Anatomy, evidence, device technique, durability, pain, and compensatory effects determine the choice.
- OnabotulinumtoxinA
- Iontophoresis
- Microwave treatment
- Gland removal
- Sympathectomy
Acetylcholine release is blocked
Repeated current sessions reduce output
Durability trades against procedure risk
Site and device determine safety
Use labeled axillary botulinum toxin
BOTOX is labeled for severe primary axillary hyperhidrosis inadequately managed by topical agents in adults. The recommended dose is 50 Units per axilla distributed intradermally across the mapped field. Product units are not interchangeable. Other sweating sites are off label: palmar treatment can weaken hand muscles, and facial treatment can cause eyelid droop.
Check toxin safety before and after treatment
Avoid injection into infected skin and screen hypersensitivity, neuromuscular disease, swallowing or respiratory problems, recent toxin exposure, aminoglycosides and muscle relaxants. The boxed warning concerns spread of toxin effects; new swallowing, speech or breathing difficulty requires immediate medical care. The label reports no definitive serious distant-spread cases at the recommended 100-Unit total axillary dose, but counseling remains necessary.
Verify the axillary dilution
For trained administration, the labeled dilution of 100 Units in 4 mL gives 25 Units/mL. A 50-Unit axillary dose therefore occupies 2 mL, distributed across the mapped field; it is not a 50-Unit dose at each injection site. Repeat when benefit diminishes, after reviewing total toxin exposure.
Use iontophoresis for palms and soles
Repeated low electrical current through tap water can reduce output. Induction often requires multiple sessions followed by maintenance. Skin breaks, implanted electrical devices, discomfort, and burn prevention require device-specific review.
Consider axillary gland procedures
Microwave thermolysis and gland removal can offer durable focal control but may involve cost, swelling, burns, neuropathy, scarring, altered sensation, or infection.
Distinguish the sweat-activated thermal patch
A prescription sodium-based patch is another clinician-applied option for adult primary axillary hyperhidrosis. Sweat activates a brief heat-producing reaction; it is not a drug patch worn overnight. FDA review specifies intact axillary skin and exposure no longer than 3 minutes, with trained removal and deactivation. Do not use on irritated or broken skin. Evidence does not establish repeated use, other body sites, secondary or diffuse disease, or every concomitant sweat-altering therapy. Confirm current device instructions and availability with the treating clinician.
Reserve sympathectomy
Endoscopic thoracic sympathectomy can interrupt neural signaling but may cause substantial compensatory sweating elsewhere. Reserve this for carefully selected refractory disease after other options have been exhausted. Benefit is more established for palmar than axillary sweating. Reversibility should not be implied.
Quick check
Checking for saved practice…
Lesson
Use Whole-Body Therapy Deliberately
Systemic therapy can reach multifocal disease but also expands anticholinergic or cardiovascular effects beyond the sweating site. These options are commonly off label and require individualized prescribing.
- Oral glycopyrrolate
- Oxybutynin
- Propranolol
- Titration
- Heat plan
Topical reach may be inadequate
Lowest useful exposure
Selected patients may use event therapy
Systemic benefit has systemic cost
Consider oral anticholinergics carefully
Oral glycopyrrolate or oxybutynin may be used off label when focal strategies are impractical or insufficient. Start low, titrate to function, and monitor dry mouth, constipation, cognition, vision, urinary retention, and heat tolerance.
Design a thermoregulation plan
Systemic sweat suppression deserves explicit counseling about hot work, sports, fever, hydration, cooling access, travel, and early symptoms of heat illness.
Use event therapy narrowly
Propranolol may help selected patients whose sweating is tightly linked to predictable performance anxiety. Screen asthma, bradycardia, hypotension, diabetes, exercise demands, and interacting rate-control drugs.
Avoid diagnostic substitution
Systemic therapy should not mask new generalized sweating, night sweats, hypoglycemia, infection, withdrawal, serotonin toxicity, or another unresolved cause.
Quick check
Checking for saved practice…
Lesson
Select Treatment Around the Person and Site
The best plan is not one universal ladder. Axillae, palms, soles, face, scalp, and generalized disease differ in evidence, delivery, risk, and effect on daily life.
- Axillary
- Palmar
- Plantar
- Craniofacial
- Shared decision
Cloth, gel, antiperspirant, or procedure
Function and pain shape choice
Specialist planning matters
Burden, cost, and preference drive adherence
Start with the site
Axillary disease may use antiperspirants, labeled topical anticholinergics, BOTOX, or procedures. Palmar and plantar disease often relies on antiperspirants, iontophoresis, or specialist procedures. Facial treatment has greater ocular and cranial risk.
Account for age
Qbrexza and Sofdra are labeled from age nine for primary axillary disease. BOTOX hyperhidrosis labeling is adult. Verify the current product label rather than generalizing one age threshold across therapies.
Review renal and reproductive uncertainty
Qbrexza labeling warns that renal failure severely impairs glycopyrronium elimination. Sofdra safety and effectiveness in renal or hepatic impairment are not established; do not invent a validated reduced-pump regimen. Neither topical product has adequate human pregnancy data or human milk data. Discuss the actual need, alternatives and infant-contact precautions with the prescriber rather than inferring safety from topical delivery.
Account for life context
Manual work, musical instruments, footwear, uniform requirements, climate, school, caregiving, cost, insurance, home electricity, and procedure tolerance all change feasibility.
Share the tradeoff
Define the patient goal, acceptable dryness, adverse-effect tolerance, maintenance burden, cost, and escalation preference. A sustainable partial response can be more valuable than an intolerable maximal response.
Quick check
Checking for saved practice…
Lesson
Measure Function and Reopen the Diagnosis
A successful trial improves daily function with acceptable adverse effects. Monitoring must also detect technique failure, medication toxicity, heat risk, skin complications, and a secondary cause that was initially missed.
- HDSS
- Patient goal
- Technique audit
- Adverse effects
- Referral
Document interference and triggers
Give each strategy a defined test
Do not count dryness alone
Reassess cause and treatment level
Document baseline and goal
Record sites, symmetry, frequency, nocturnal symptoms, triggers, HDSS or similar severity, clothing changes, grip, footwear, skin infection, sleep, mood, and the patient-defined target.
Audit technique before escalation
Confirm the exact product, amount, site, dryness, shaving and shower timing, frequency, handwashing, occlusion, antiperspirant induction, iontophoresis schedule, and adherence.
Track benefit and harm
Monitor function alongside dermatitis, dry mouth, constipation, vision, pupils, urinary symptoms, cognition, heat tolerance, compensatory sweating, procedure pain, and cost.
Escalate the right problem
Refer refractory focal disease for dermatology or procedural expertise. Promptly evaluate fever, weight loss, night sweats, hypoglycemia, chest symptoms, neurologic change, severe heat illness, or new generalized disease.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 35 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- International Hyperhidrosis Society Axillary Treatment Guideline
- International Hyperhidrosis Society Diagnosis Guidance
- International Hyperhidrosis Society Sweat Physiology
- American Academy of Dermatology Hyperhidrosis Diagnosis and Treatment
- DailyMed Qbrexza Glycopyrronium Cloth
- DailyMed Sofdra Sofpironium Gel
- FDA N-SWEAT Thermal Patch Review
- FDA Sofdra Drug Trials Snapshot
- DailyMed BOTOX OnabotulinumtoxinA